We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App




Knee Lubricant Reduces Arthritic Pain 38%

By HospiMedica staff writers
Posted on 22 Aug 2002
Print article
Two studies have shown that a fluid called Synvisc can provide significant improvement in pain, stiffness, and physical functioning in patients with osteoarthritis of the knee. The studies were published in the July 2002 issue of Osteoarthritis and Cartilage.

As people age, the synovial fluid in their knees becomes thinner and loses its elasticity and viscosity, causing pain. Now a treatment made from a substance called hyluronan, found in normal joint fluid, can be injected into the knee, providing lubrication and serving as a shock absorber to cushion the knee joint.

In the studies, 255 patients at 14 sites were randomized to receive either care with Synvisc or such options as acetaminophen, nonsteroidal anti-inflammatory drugs, physical therapy, ice, heat, or weight reduction. The results showed that the patients who received Synvisc had outcomes superior to the control group for all of the primary and secondary inputs. Specifically, the Synvisc group improved 38% from baseline in a validated measurement of osteoarthritis pain, compared with a 13% improvement for the control group. The same significant differences were seen in joint stiffness and physical functioning.

"The improved quality of life gained by patients in our study who were treated with Synvisc appeared to be well worth the added costs associated with the treatment,” said George W. Torrance, Ph.D., from McMaster University in Hamilton (Canada).

Synvisc is manufactured by Genzyme Biosurgery (Cambridge, MA, USA). Synvisc is administered in three injections over a 15-day period and can provide up to six months of osteoarthritic pain relief, says the company.




Related Links:
Genzyme
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Surgical Booms
AIRport
New
Phlebotomy Cart
TR-65J38

Print article

Channels

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.